Paul Thomen

Monday, 15 July 2013

Myeloproliferative Disorders – Pipeline Review, H1 2013

‘Myeloproliferative Disorders – Pipeline Review, H1 2013, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Myeloproliferative Disorders – Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.


- A snapshot of the global therapeutic scenario for Myeloproliferative Disorders.
- A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myeloproliferative Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myeloproliferative Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content

Global Markets Direct Report Coverage 9
Myeloproliferative Disorders Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Myeloproliferative Disorders 11
Myeloproliferative Disorders Therapeutics under Development by Companies 13
Myeloproliferative Disorders Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Myeloproliferative Disorders Therapeutics - Products under Development by Companies 20
Myeloproliferative Disorders Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Myeloproliferative Disorders Therapeutics Development 23
Bristol-Myers Squibb Company 23
Sanofi-Aventis 24
AstraZeneca PLC 25
Eli Lilly and Company 26
Genentech, Inc. 27
Gilead Sciences, Inc. 28
Merck & Co., Inc. 29
Nanotherapeutics, Inc. 30
Novartis AG 31

Explore More Reports @

No comments:

Post a Comment

Note: only a member of this blog may post a comment.